From 24/7 Wall St. · Chris Lange · · 1m 10s
Pfizer's Dividend Freeze Raises Cash Flow Question
Pfizer's dividend freeze tests cash flow as patent expirations loom.
In brief
Pfizer's dividend freeze tests cash flow as patent expirations loom. Pfizer can maintain its $0.43 quarterly dividend through 2029 but faces thin cash flow and debt challenges. Originally reported by 24/7 Wall St..
Pfizer's Dividend Freeze
Pfizer declared its quarterly dividend at $0.43 per share on Oct 6, 2026, the same amount since early 2025.
Dividend Payout Ratio
The $1.72 annual dividend works out to a payout ratio of 57% to 61% against 2026 EPS guidance of $2.80 to $3.00.
Cash Flow Shortfall
In 2025, dividends cost $9.77 billion while operating cash flow minus capital spending was $9.08 billion.
Debt and Leverage
Total debt rose from $35.8 billion in 2022 to $63.2 billion by June 30, 2026, with cash at $976 million.
Patent Expiration Impact
Generic competition will cost Pfizer $1.1 billion in revenue this year with larger losses from patent expirations coming later.
CEO's Dividend Commitment
Chief executive Albert Bourla stated Pfizer will maintain the dividend through patent expiration years and grow it after 2029.
“We feel extremely confident that, even in the most stretched scenarios that we are running, we will be able to maintain our dividend. So I want, once and for all, to make that clear to all: the dividend will be maintained, and eventually, after the LOE period, we will start growing it again.”
Comparison to Competitors
Bristol-Myers Squibb raised its dividend to $0.63 per quarter while Merck faced $9.0 billion and $5.7 billion one-time charges.
The key point
Pfizer can maintain its $0.43 quarterly dividend through 2029 but faces thin cash flow and debt challenges.
